KR20180004263A - 염증 또는 신경병성 통증의 치료 방법 - Google Patents

염증 또는 신경병성 통증의 치료 방법 Download PDF

Info

Publication number
KR20180004263A
KR20180004263A KR1020177035499A KR20177035499A KR20180004263A KR 20180004263 A KR20180004263 A KR 20180004263A KR 1020177035499 A KR1020177035499 A KR 1020177035499A KR 20177035499 A KR20177035499 A KR 20177035499A KR 20180004263 A KR20180004263 A KR 20180004263A
Authority
KR
South Korea
Prior art keywords
compound
effective amount
pharmaceutically acceptable
acceptable salt
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177035499A
Other languages
English (en)
Korean (ko)
Inventor
재클린 로레인 블랭크맨
제이슨 로버트 클래퍼
알 앨런 비 에제코위츠
이언 피터 프레이저
셰럴 에이 그라이스
토드 케이 존스
그레이 폴 오닐
아치 웨인 주니어 서스턴
채닝 로드니 빌스
Original Assignee
어바이드 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어바이드 테라퓨틱스, 인크. filed Critical 어바이드 테라퓨틱스, 인크.
Publication of KR20180004263A publication Critical patent/KR20180004263A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020177035499A 2015-05-11 2016-05-10 염증 또는 신경병성 통증의 치료 방법 Ceased KR20180004263A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562159770P 2015-05-11 2015-05-11
US62/159,770 2015-05-11
US201662297670P 2016-02-19 2016-02-19
US62/297,670 2016-02-19
PCT/US2016/031668 WO2016183097A1 (en) 2015-05-11 2016-05-10 Methods of treating inflammation or neuropathic pain

Publications (1)

Publication Number Publication Date
KR20180004263A true KR20180004263A (ko) 2018-01-10

Family

ID=57249499

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177035499A Ceased KR20180004263A (ko) 2015-05-11 2016-05-10 염증 또는 신경병성 통증의 치료 방법

Country Status (14)

Country Link
US (3) US10450302B2 (enExample)
EP (1) EP3294731A4 (enExample)
JP (2) JP2018515460A (enExample)
KR (1) KR20180004263A (enExample)
CN (2) CN113413387A (enExample)
AU (3) AU2016262459A1 (enExample)
BR (1) BR112017024253A2 (enExample)
CA (1) CA2984480A1 (enExample)
EA (1) EA201792496A1 (enExample)
HK (1) HK1252658A1 (enExample)
IL (2) IL255239A0 (enExample)
MX (2) MX2017014344A (enExample)
SG (1) SG10202012002TA (enExample)
WO (1) WO2016183097A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2982694T3 (es) 2012-01-06 2024-10-17 H Lundbeck As Compuestos de carbamato para su uso en tratamiento
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
BR112017024253A2 (pt) 2015-05-11 2018-07-24 Abide Therapeutics Inc métodos de tratamento de inflamação ou dor neuropática.
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US10463753B2 (en) 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
HUE056973T2 (hu) 2016-11-16 2022-04-28 H Lundbeck As MAGL inhibitor kristályos formája
CA3043609A1 (en) * 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
JOP20190105A1 (ar) * 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
WO2021062232A1 (en) * 2019-09-26 2021-04-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for reducing rewarding effects of morphine without affecting its analgesic effects
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
MX2022013224A (es) * 2020-04-21 2022-11-14 H Lundbeck As Sintesis de un inhibidor de la monoacilglicerol lipasa.
US20210369704A1 (en) * 2020-05-29 2021-12-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for preventing and treating headache through enhancing 2-arachydonyl glyerol activity
KR20240128870A (ko) 2021-12-29 2024-08-27 싸이 테라퓨틱스, 인크. 모노아실글리세롤 리파아제(magl) 억제
EP4499065A1 (en) * 2022-03-31 2025-02-05 Mayo Foundation for Medical Education and Research Methods and materials for treating pancreatic diseases and disorders
AU2023264787A1 (en) 2022-05-04 2024-10-31 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593586A (enExample) 1967-10-17 1970-06-01
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS6183073A (ja) 1984-10-01 1986-04-26 Oki Electric Ind Co Ltd 印字装置の用紙送り方法
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
WO1989011794A1 (fr) 1988-06-07 1989-12-14 Rikagaku Kenkyusho Inhibiteur de la croissance de plantes
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
WO1992018106A1 (fr) 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
WO1993009785A1 (en) 1991-11-22 1993-05-27 Procter & Gamble Pharmaceuticals, Inc. Risedronate delayed-release compositions
AU3226993A (en) 1991-11-27 1993-06-28 E.I. Du Pont De Nemours And Company Herbicidal acylated amino-(phenyl- or pyridinyl- or thienyl-)-phenyl derivatives
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
ES2180548T3 (es) 1992-10-16 2003-02-16 Nippon Shinyaku Co Ltd Metodo de obtencion de matrices de cera.
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
DE69408873T2 (de) 1993-12-22 1998-07-09 Shell Int Research Verfahren zur herstellung von carbamaten
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
WO1997018196A1 (en) 1995-11-15 1997-05-22 Zeneca Limited Herbicidal substituted pyrazole compounds
WO1998000408A1 (en) 1996-07-02 1998-01-08 Novartis Ag N-phenylimino heterocyclic derivatives and their use as herbicides
RU2167150C2 (ru) 1998-03-25 2001-05-20 Фокин Александр Васильевич Полифторалкил-n-арилкарбаматы, обладающие антимикробной активностью
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
WO2001025486A1 (en) 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Methods for identifying rna binding compounds
EP1201298A1 (en) 2000-10-24 2002-05-02 Urea Casale S.A. Carbamate condensation unit
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
MXPA04008073A (es) * 2002-02-20 2004-11-26 Abbott Lab Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide.
DE10348022A1 (de) 2003-10-15 2005-05-25 Imtm Gmbh Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen
FR2864080B1 (fr) 2003-12-23 2006-02-03 Sanofi Synthelabo Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique
AU2003300702A1 (en) 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Process for preparing carbamates
BRPI0507499A (pt) 2004-02-18 2007-07-24 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável ou hidrato dos mesmos, composição farmacêutica, uso do composto, e, métodos para tratar distúrbios mediados por mglur 5 e para inibir a ativação de receptores de mglur 5
WO2006066914A2 (en) 2004-12-23 2006-06-29 F. Hoffmann-La Roche Ag Carbamate substituted imidazo- and pyrrolo-pyridines as protein kinase inhibitors
NZ568700A (en) 2005-11-28 2012-03-30 Marinus Pharmaceuticals Solid stabilized particulate formulations comprising ganaxolone
JP2009523729A (ja) 2006-01-13 2009-06-25 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎の治療方法
EP1938804A1 (en) 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
WO2008106047A2 (en) 2007-02-26 2008-09-04 Kosan Biosciences Incorporated Carbamate compounds
FR2938341A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
US8188098B2 (en) 2008-05-19 2012-05-29 Hoffmann-La Roche Inc. GPR119 receptor agonists
EP2328897A1 (en) 2008-07-16 2011-06-08 Schering Corporation Bicyclic heterocycle derivatives and their use as gpcr modulators
CA2743861A1 (en) 2008-11-14 2010-05-20 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
WO2010063802A1 (en) 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
CN102548558B (zh) 2009-03-23 2014-04-30 Msdk.K.公司 具有Aurora A选择性抑制作用的氨基吡啶衍生物
UA107791C2 (en) 2009-05-05 2015-02-25 Dow Agrosciences Llc Pesticidal compositions
PL2497082T3 (pl) 2009-11-03 2013-12-31 Bayer Ip Gmbh Fluorouretany jako dodatek w formulacji fotopolimerowej
FR2960875B1 (fr) 2010-06-04 2012-12-28 Sanofi Aventis Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique
EP4647076A2 (en) 2012-01-06 2025-11-12 Les Laboratoires Servier Therapeutically active compounds and their methods of use
ES2982694T3 (es) * 2012-01-06 2024-10-17 H Lundbeck As Compuestos de carbamato para su uso en tratamiento
CN104379578B (zh) * 2012-03-19 2017-06-09 阿比德治疗公司 氨基甲酸酯化合物及其制备和使用方法
WO2013159095A1 (en) * 2012-04-20 2013-10-24 Anderson Gaweco Ror modulators and their uses
DK2914248T4 (da) 2012-11-02 2024-01-02 Vertex Pharma Farmaceutiske sammensætninger til behandlingen af cftr medierede sygdomme
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
WO2015179559A2 (en) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
BR112017024253A2 (pt) 2015-05-11 2018-07-24 Abide Therapeutics Inc métodos de tratamento de inflamação ou dor neuropática.
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
HUE056973T2 (hu) 2016-11-16 2022-04-28 H Lundbeck As MAGL inhibitor kristályos formája
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Also Published As

Publication number Publication date
CN107849021A (zh) 2018-03-27
US20180099951A1 (en) 2018-04-12
US20210230145A1 (en) 2021-07-29
US20200055841A1 (en) 2020-02-20
MX2017014344A (es) 2018-04-11
EP3294731A4 (en) 2018-10-24
SG10202012002TA (en) 2021-01-28
JP2018515460A (ja) 2018-06-14
AU2016262459A1 (en) 2017-12-21
EP3294731A1 (en) 2018-03-21
WO2016183097A1 (en) 2016-11-17
JP2022008597A (ja) 2022-01-13
AU2022203543A1 (en) 2022-06-16
US10450302B2 (en) 2019-10-22
CA2984480A1 (en) 2016-11-17
BR112017024253A2 (pt) 2018-07-24
CN113413387A (zh) 2021-09-21
HK1252658A1 (zh) 2019-05-31
IL255239A0 (en) 2017-12-31
EA201792496A1 (ru) 2018-04-30
IL284299A (en) 2021-07-29
MX2021014815A (es) 2022-01-18
US11034674B2 (en) 2021-06-15
AU2020213382A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
US11034674B2 (en) Methods of treating inflammation or neuropathic pain
JP7020756B2 (ja) 対象の心血管イベントのリスクを低減する方法
US20220226262A1 (en) Methods of treating doose syndrome using fenfluramine
Ohlstein et al. A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder
ES2846176T3 (es) Métodos para reducir el riesgo de un evento cardiovascular en un sujeto en tratamiento con estatinas usando éster etílico del ácido eicosapentaenoico
Lewek et al. Dyslipidaemia management in pregnant patients: a 2024 update
JP2019501190A (ja) Ｄｇｌａを含む薬学的組成物及びその使用
KR20170010058A (ko) Dgla를 포함하는 약제학적 조성물 및 그의 용도
Leslie Alvimopan for the management of postoperative ileus
KR20240152410A (ko) 아티카프란트를 포함하는 조성물
Vasiliu Current evidence and future perspectives in the exploration of sleep-related eating disorder–a systematic literature review
HK40061449A (en) Methods of treating inflammation or neuropathic pain
Seifert Drugs easily explained
Spierings et al. A randomized, rater-blinded, crossover study of the effects of oxymorphone extended release, fed versus fasting, on cognitive performance as tested with CANTAB in opioid-tolerant subjects
US20250375417A1 (en) Orexin receptor 2 (ox2r) agonist for use in narcolepsy type 1 (nt1)
US20240398771A1 (en) Treatment of scleroderma and raynaud's syndrome
RU2784524C2 (ru) Способы лечения синдрома дузе с использованием фенфлурамина
TW202521100A (zh) 使用ｇｌｐ－１受體促效劑及第二活性劑之組合治療睡眠呼吸中止之方法及組合物
WO2024211216A1 (en) Cilnidipine and a p-glycoprotein inhibitor for treating pain
Fung The Efficacy of Curcumin in Cognitive Impairment
HK40029279A (en) Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
Van der Westhuizen Obesity: evidence-based pharmacy practice

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171208

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210324

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20220503

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230601

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20231106

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230601

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I